193 related articles for article (PubMed ID: 37568304)
1. Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function.
Dunaway Young S; Montes J; Glanzman AM; Gee R; Day JW; Finkel RS; Darras BT; De Vivo DC; Gambino G; Foster R; Wong J; Garafalo S; Berger Z;
J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568304
[TBL] [Abstract][Full Text] [Related]
2. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
[TBL] [Abstract][Full Text] [Related]
3. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
[TBL] [Abstract][Full Text] [Related]
4. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
6. Nusinersen for adults with spinal muscular atrophy.
Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
[TBL] [Abstract][Full Text] [Related]
7. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
[TBL] [Abstract][Full Text] [Related]
8. Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: A retrospective cohort study.
Shimizu-Motohashi Y; Chiba E; Mizuno K; Yajima H; Ishiyama A; Takeshita E; Sato N; Oba M; Sasaki M; Ito S; Komaki H
Brain Dev; 2023 Mar; 45(3):161-170. PubMed ID: 36460551
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression.
Ip HNH; Yu MKL; Wong WHS; Liu A; Kwan KYH; Chan SHS
J Neuromuscul Dis; 2024; 11(2):349-359. PubMed ID: 38363614
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
[TBL] [Abstract][Full Text] [Related]
11. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
12. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.
Gavriilaki M; Moschou M; Papaliagkas V; Notas K; Chatzikyriakou E; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
Neurotherapeutics; 2022 Mar; 19(2):464-475. PubMed ID: 35178673
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy.
Stolte B; Totzeck A; Kizina K; Bolz S; Pietruck L; Mönninghoff C; Guberina N; Oldenburg D; Forsting M; Kleinschnitz C; Hagenacker T
Ther Adv Neurol Disord; 2018; 11():1756286418803246. PubMed ID: 30305849
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
[TBL] [Abstract][Full Text] [Related]
16. Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3.
Wolfe A; Stimpson G; Ramsey D; Coratti G; Dunaway Young S; Mayhew A; Pane M; Rohwer A; Muni Lofra R; Duong T; O'Reilly E; Milev E; Civitello M; Sansone VA; D'Amico A; Bertini E; Messina S; Bruno C; Albamonte E; Mazzone E; Main M; Montes J; Glanzman AM; Zolkipli-Cunningham Z; Pasternak A; Marini-Bettolo C; Day JW; Darras BT; De Vivo DC; Baranello G; Scoto M; Finkel RS; Mercuri E; Muntoni F;
J Neuromuscul Dis; 2024; 11(3):665-677. PubMed ID: 38427497
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Health-Related Quality of Life in Adult Spinal Muscular Atrophy Under Nusinersen Treatment-A Pilot Study.
Thimm A; Brakemeier S; Kizina K; Munoz Rosales J; Stolte B; Totzeck A; Deuschl C; Kleinschnitz C; Hagenacker T
Front Neurol; 2021; 12():812063. PubMed ID: 35140677
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
[TBL] [Abstract][Full Text] [Related]
19. Improvement in functional motor scores in patients with non-ambulatory spinal muscle atrophy during Nusinersen treatment in South Korea: a single center study.
Yoon JA; Jeong Y; Lee J; Lee DJ; Lee KN; Shin YB
BMC Neurol; 2024 Jun; 24(1):210. PubMed ID: 38902631
[TBL] [Abstract][Full Text] [Related]
20. Nusinersen for spinal muscular atrophy types II and III: a retrospective single-center study in South Korea.
Shin HJ; Na JH; Lee H; Lee YM
World J Pediatr; 2023 May; 19(5):450-459. PubMed ID: 36441395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
